

**Preferred Drug List Committee
Meeting Agenda, Open Session
September 18th, 2013 10:00 a.m.**

Meeting Location

HP Enterprise Services ~ Capital Room
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, Kansas 66619

Board Members

Taylor Gill, Pharm.D., BCPS
Terry 'Lee' Mills, Jr., M.D.
Jonalan Smith, Pharm.D.
Dennis Tietze, M.D.

Robert Haneke, Pharm.D.
Matthew Schlotterback, M.D.
Donna Sweet, M.D.

KDHE-DHCF Staff

Brandy Allen
Kelley Melton, Pharm.D.

Katy Brown, Pharm.D.

HP Enterprise Services / HID Staff

Karen Kluczykowski, R.Ph.

Nicole Ellermeier, Pharm.D.

- I. Welcome & Announcements
- II. Review & Approval of March 13th, 2013 Meeting Minutes
- III. Hepatitis C Protease Inhibitors – New Class Review (Incivek & Victrelis)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations
- IV. Non-Steroidal Anti-Inflammatory Drugs (Ophthalmic) – Class Re-review: New Agent (Ilevro)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations
- V. Dipeptidyl Peptidase-4 Inhibitors – Class Re-review: New Agents (Nesina)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations
- VI. Fixed Dose Combinations for Diabetes – Class Re-review: New Agent (Oseni, Kazano)
 - a. Public Comment*

- b. Committee Discussion/Recommendations
- VII. Urologics: Beta-3 adrenergic agonists– New Class Review (Myrbetriq)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- VIII. Triptans – Class Re-review: New Agent (Zecuity)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- IX. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors – New Class Review (Invokana)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- X. Oral Multiple Sclerosis Agents – New Class Review (Aubagio, Gilenya, Tecfidera)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- XI. Proton Pump Inhibitors – Class Re-review: New Agent (Aciphex Sprinkles)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- XII. Inhaled Long-Acting Beta2-Agonists/Corticosteroids – Class Re-review: New Agent (Breo Ellipta)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- XIII. Adjunct Anti-Epileptics – Class Re-review: New Agents (Oxtellar XR)
- a. Public Comment*
 - b. Committee Discussion/Recommendations
- XIV. Open Public Comment
- XV. Adjourn

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board’s discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE.**